Trusted Resources: Education
Scientific literature and patient education texts
Depression and Anxiety in Patients With AL Amyloidosis as Assessed by the SF-36 Questionnaire
source: Amyloid: The International Journal of Experimental and Clinical Investigation
year: 2016
authors: Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V
summary/abstract:Background:
Our study examines depression and anxiety in patients with immunoglobulin light chain (AL) amyloidosis, and determines the associations between the mental health problems and patient characteristics (age, gender, race, marital status, alcohol consumption, smoking status and cardiac involvement).
Methods:
Patients with AL amyloidosis who completed the 36-item Short Form General Health Survey (SF-36) during initial evaluation at a single center were studied. The SF-36 included assessments of depression, anxiety, role limitation due to emotional problems and the mental health subscale score.
Results:
From 1226 patients with AL amyloidosis, 37.0% reported depression and 46.7% reported anxiety. Patients with cardiac amyloidosis reported more anxiety (odds ratio (OR) = 1.29, 95% confidence interval (CI) 1.03-1.61) and role limitation due to emotional problems (OR = 1.32, 95%CI 1.05-1.65). No significant association between cardiac involvement and depression was found (OR = 1.22, 95%CI 0.97-1.54). Men reported less anxiety (OR = 0.72, 95%CI 0.57-0.91). Patients ≥65 years experienced greater role limitation (OR = 1.36, 95%CI 1.08-1.71). Smokers (p = 0.019) and women (p = 0.006) scored lower on mental health subscales.
Conclusions:
Many patients with AL amyloidosis suffer from depression, anxiety and functional limitations. Psychiatric assessment and treatment is important, and further research is needed to clarify the long-term effects of depression and anxiety in AL amyloidosis.
organization: Boston Medical Center, USA; Boston University School of Public Health, USA; Boston University School of Medicine, USADOI: 10.1080/13506129.2016.1208081
read more
Related Content
-
Combination Therapy Holds Promise for Newly Diagnosed Systemic AL Amyloidosis PatientsUpdated research regarding the ANDROMEDA...
-
Introduction to Light Chain (AL) Amyloidosis Webinarhttps://www.youtube.com/watch?v=FBETo4zD...
-
Future AL Amyloidosis Treatmenthttps://www.youtube.com/watch?v=K25lurau...
-
U.S. Department of Veterans Affairs: AL Amyloidosis and Agent OrangeAL Amyloidosis and Agent Orange Veteran...
-
Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) W...Background: Systemic AL amyloidosis is ...
-
ISA 2020 | New Organ Response Criteria for AL Amyloidosishttps://www.youtube.com/watch?v=h40cJ7NX...
-
ISA 2020 | The Use of Solid Organ Transplant in AL Amyloidosishttps://www.youtube.com/watch?v=qkSRpmb-...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.